Szymkowiak J, Fojt E
I Oddziału Chorób Wewnetrznych Górniczego Centrum Medycznego, Katowicach.
Wiad Lek. 1993 Jan-Feb;46(1-2):56-61.
Aztreonam is the first synthetic monobactam used in practical medicine. It is effective in Gram-negative aerobe infections. It inhibits the growth of most Enterobacteriaceae in concentrations below 2 mg/ml, and of Pseudomonas aeruginosa below 16 mg/ml. It shows a widespread, distribution achieving effective therapeutic concentration there, where infections are seen most frequently. The half-life is from 1.6 to 2.0 hours. It can be administered to patients every 8 and 12 hours in single parenteral doses of 0.5, 1.0, and 2.0 g. Aztreonam is a non-toxic antibiotic, a weak hapten with slight allergenicity. It has found therapeutic use together with the antibiotics directed against aerobic and anaerobic bacterial Gram-positive flora, and it is used in the therapy directed against infections with Gram-negative aerobes. It is an effective antibiotic in nosocomial infections, in oncological patients with neutropenia, and in elderly patients.
氨曲南是实际医学中使用的第一种合成单环β-内酰胺类抗生素。它对革兰氏阴性需氧菌感染有效。在浓度低于2毫克/毫升时，它能抑制大多数肠杆菌科细菌的生长，在低于16毫克/毫升时能抑制铜绿假单胞菌的生长。它分布广泛，在感染最常见的部位能达到有效的治疗浓度。半衰期为1.6至2.0小时。可以每8至12小时给患者单次静脉注射0.5克、1.0克和2.0克的剂量。氨曲南是一种无毒抗生素，是一种弱半抗原，致敏性轻微。它已与针对需氧和厌氧革兰氏阳性菌菌群的抗生素一起用于治疗，并且用于针对革兰氏阴性需氧菌感染的治疗。它在医院感染、患有中性粒细胞减少症的肿瘤患者以及老年患者中是一种有效的抗生素。
